Imatinib Dr. Reddy’s (Imatinib)

Imatinib inhibits the activity of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases by binding to their ATP‑binding sites. This blocks phosphorylation events that are essential for malignant cell proliferation and survival, leading to apoptosis of cancer cells and interruption of tumor‑driving signaling pathways.

The dosage of Imatinib Dr. Reddy’s is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and response to therapy. Only a qualified healthcare professional should determine the appropriate dose and schedule.

The safety of Imatinib in pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, and it should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Imatinib was the first BCR‑ABL inhibitor approved for CML and GIST and remains a standard first‑line option. Newer agents such as dasatinib or nilotinib may offer faster molecular responses but can have different safety profiles and drug‑interaction potentials. Choice of therapy depends on disease characteristics, patient tolerance, and physician judgment.

Store the tablets at room temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat, and direct light. Do not refrigerate or freeze the product, and keep it out of reach of children.

Imatinib Dr. Reddy’s is taken orally, usually once daily, with a glass of water. It may be swallowed with or without food; however, consistent intake with respect to meals helps maintain stable absorption. Patients should follow the prescribing physician’s instructions regarding timing and any required dietary considerations.

The most serious adverse events include severe neutropenia or leukopenia, hepatotoxicity, cardiac dysfunction such as reduced left‑ventricular ejection fraction, and pulmonary arterial hypertension. Prompt medical evaluation is essential if patients experience signs of infection, jaundice, shortness of breath, or unexplained swelling.

Imatinib is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Patients with severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant without a clear therapeutic justification should avoid the drug. A thorough medical assessment is required before initiating therapy.